Ping An Biomedical Co., Ltd. financials

Ping An Biomedical Co., Ltd. reports to SEC EDGAR in CNY (it files a 20-F/40-F as a foreign private issuer), so every monetary figure below is in CNY as filed, not US dollars.
PASW CIK 0001897532

Source: EDGAR filings · Built 2026-06-19T02:56:56Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2025FY 2025
EBITDA -14.70M 8.20K 645.24K
Working Capital 40.62M -10.27M
Net Debt 9.30M 10.68M
Gross Margin 2.78% 6.18% 5.14%
Operating Margin -43.05% -0.00% 0.74%
Net Margin -37.57% -1.47% -1.20%
Return on Equity (ROE) -28.36% 17.86% 16.96%
Return on Assets (ROA) -18.75% -2.26%
Current Ratio 2.76× 0.84×
Debt-to-Equity 0.23× -1.50×
Effective Tax Rate -12.64% 88.10% -2484.34%
Cash Conversion Ratio 0.50× -11.39× 6.12×
Accruals Ratio -0.09× -0.28×

Income Statement

Concept FY 2025FY 2025FY 2025
Revenues 4.80M 87.62M 82.56M
Cost of Revenue 4.66M 82.21M 78.32M
Gross Profit 133.38K 5.42M 4.24M
Operating Expenses 2.20M 5.42M 3.63M
Operating Income (Loss) -2.07M -2.04K 612.48K
Income Tax Expense (Benefit) 260.65K -601.46K -1.04M
Net Income (Loss) Attributable to Parent -1.80M -1.28M -993.94K
Earnings Per Share, Basic $-0.10 ¥-0.07 ¥-0.06
Weighted Average Number of Shares Outstanding, Basic 18.48M 18.00M 18.00M
Earnings Per Share, Diluted $-0.10 ¥-0.07 ¥-0.06
Weighted Average Number of Shares Outstanding, Diluted 18.48M 18.00M 18.00M

Balance Sheet

Concept FY 2025FY 2025FY 2025
Cash and Cash Equivalents, at Carrying Value 164.70K 130.92K 591.87K
Assets, Current 8.95M 53.31M
Assets 9.61M 56.85M
Liabilities, Current 3.24M 63.58M
Liabilities 3.26M 64.04M
Stockholders' Equity Attributable to Parent 6.36M -7.19M -5.86M
Common Stock, Shares, Outstanding 20.50M 18.00M

Cash Flow Statement

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PASW CIK 0001897532), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SSSSL

SuRo Capital Corp.

CCNEP

CNB FINANCIAL CORP/PA

KZIA

Kazia Therapeutics Limited.